Graves disease

Graves disease
Name	Graves disease

Graves disease Graves disease is an autoimmune disorder that predominantly affects the thyroid gland and commonly causes hyperthyroidism. It is associated with immune dysregulation involving thyroid-stimulating immunoglobulins and can manifest with systemic, ophthalmic, and dermatologic findings. Clinical management spans endocrinology, surgery, ophthalmology, and immunology.

Signs and symptoms

Patients often present with symptoms of thyrotoxicosis such as palpitations, weight loss, heat intolerance, tremor, and anxiety; descriptions in clinical practice are documented in sources like World Health Organization, American Thyroid Association, National Institutes of Health, Mayo Clinic, and Johns Hopkins Hospital. Physical findings can include a diffusely enlarged thyroid (goiter), brisk reflexes, and warm moist skin noted in textbooks from Oxford University Press, Cambridge University Press, and Elsevier. Specific extrathyroidal manifestations include Graves ophthalmopathy with eyelid retraction, proptosis, and diplopia; these features are managed in centers such as Massachusetts Eye and Ear Infirmary, Bascom Palmer Eye Institute, and described in literature from American Academy of Ophthalmology, European Thyroid Association, and Royal College of Physicians. Pretibial myxedema and digital clubbing are rarer cutaneous signs reported in cases discussed by American Academy of Dermatology and specialty clinics at Cleveland Clinic.

Cause and pathophysiology

Graves disease arises from autoantibodies (thyroid-stimulating immunoglobulins) that bind the thyrotropin receptor, stimulating thyroid hormone production; this mechanism is detailed in reviews from New England Journal of Medicine, The Lancet, Nature Reviews Immunology, Journal of Clinical Endocrinology & Metabolism, and monographs published by Springer Nature. Genetic predisposition involves loci identified in genome studies by institutions such as Broad Institute, Wellcome Trust Sanger Institute, and cohorts like UK Biobank and Framingham Heart Study. Environmental triggers implicated include smoking (epidemiology in reports by Centers for Disease Control and Prevention, Public Health England), iodine exposure (analyses from International Council for the Control of Iodine Deficiency Disorders), and infections investigated by teams at Karolinska Institutet and Harvard T.H. Chan School of Public Health. Immune pathways engage T and B lymphocytes, cytokines, and costimulatory molecules discussed in articles from Cell, Immunity, and proceedings of Cold Spring Harbor Laboratory conferences.

Diagnosis

Diagnosis combines clinical assessment, biochemical testing (elevated free thyroxine and suppressed thyroid-stimulating hormone), and serology for thyroid-stimulating antibodies as recommended by guidelines from American Thyroid Association, European Thyroid Association, Endocrine Society, National Institute for Health and Care Excellence, and consensus statements from International Thyroid Congress. Imaging modalities include thyroid ultrasound performed in radiology departments like Mayo Clinic Radiology, radionuclide uptake scans using technetium or iodine used at centers such as Memorial Sloan Kettering Cancer Center and antibody assays validated by laboratories at Quest Diagnostics and Mayo Clinic Laboratories. Ophthalmic evaluation for orbital involvement often refers patients to services at Massachusetts Eye and Ear Infirmary, Bascom Palmer Eye Institute, and international eye hospitals described in publications from American Academy of Ophthalmology.

Treatment

Antithyroid drugs (methimazole, propylthiouracil) are first-line therapies in many regions according to protocols from American Thyroid Association, European Thyroid Association, Endocrine Society, World Health Organization, and national guidelines such as those from National Health Service. Radioactive iodine ablation is performed in nuclear medicine units at institutions like Johns Hopkins Hospital, UCLA Health, and Mount Sinai Health System and is chosen according to recommendations by panels convened at International Atomic Energy Agency. Thyroidectomy is undertaken by endocrine surgeons trained through programs at American College of Surgeons, Royal College of Surgeons, and high-volume centers including Mayo Clinic and Cleveland Clinic. Management of Graves ophthalmopathy may require corticosteroids, orbital radiotherapy, or biologic therapy (e.g., teprotumumab) discussed in trials published in New England Journal of Medicine and guidelines from American Academy of Ophthalmology and European Group on Graves' Orbitopathy. Multidisciplinary care models are advocated by tertiary referral centers such as Massachusetts General Hospital and collaborative networks like Thyroid Federation International.

Complications and prognosis

Untreated thyrotoxicosis can lead to arrhythmias (atrial fibrillation), heart failure, osteoporosis, and thyroid storm; cardiology and endocrinology literature from American Heart Association, European Society of Cardiology, British Heart Foundation, Journal of Bone and Mineral Research, and The Lancet describe these outcomes. Ophthalmopathy can progress to compressive optic neuropathy requiring urgent intervention per recommendations from American Academy of Ophthalmology and specialized orbital units at Bascom Palmer Eye Institute. Long-term prognosis depends on treatment choice, age, comorbidity, and access to care as documented by cohort studies from Framingham Heart Study, UK Biobank, NORD registries, and health services research in Health Affairs.

Epidemiology

Graves disease exhibits geographic and demographic variation; incidence and prevalence data are summarized in reports by World Health Organization, Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, and national registries such as Swedish National Patient Register and Danish National Patient Registry. It is more common in women and often presents between the ages reported in population studies from Nurses' Health Study, UK Biobank, and cohort analyses at Karolinska Institutet. Risk modifiers including smoking, iodine intake, and family history are documented in epidemiologic papers from Harvard T.H. Chan School of Public Health, Johns Hopkins Bloomberg School of Public Health, and meta-analyses in BMJ and The Lancet.

History and society

Descriptions of hyperthyroid states date back to clinical observations from physicians at institutions like Guy's Hospital, St Thomas' Hospital, and historical case series in journals such as The Lancet and BMJ. The eponym derives from the 19th-century work of clinicians in hospitals including Royal Victoria Infirmary and publications in proceedings of the Royal Society of Medicine. Advances in treatment—surgical approaches developed by surgeons trained through Royal College of Surgeons programs, antithyroid drug discovery reported in chemical literature, and the introduction of radioactive iodine after work at University of California, Berkeley and Massachusetts Institute of Technology—are chronicled in histories at Wellcome Collection and museum archives of Royal College of Physicians. Social impacts, patient advocacy, and support networks are active through organizations like Thyroid Federation International, American Thyroid Association, British Thyroid Foundation, and patient information resources at Mayo Clinic and National Institutes of Health.

Category:Autoimmune diseases